- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
The TocriscreenTM PRO service allows you to design a completely custom compound library to meet your exact screening requirements. With this cherry-picking service, you can choose compounds from a list over 3,700 products from the Tocris catalog (minimum order ~80 compounds), as well as customize the format of the compounds (dry powder or in solution), and the tubes they are supplied in.
The bioactive compounds available through the Tocriscreen PRO service cover a wide range of targets, such as GPCRs, ion channels, enzymes, kinases, nuclear receptors and transporters, and all major research areas and product actions. Included are commonly used research standards, novel research tools, and pharmacologically active components of FDA-approved therapeutics.
As well as requesting a completely custom library, the Tocriscreen PRO service also allows you to select a pre-defined list of compounds. Currently available lists are:
The Tocris scientific team are ready to help you with choosing compounds and designing your bioactive compound library to fit your research needs. To help our team get started on your inquiry, please provide as much information as possible about your required compound format, research areas and targets, and if you require one of the pre-defined lists outlined above.
Please submit your requirements through the compound library inquiry form.
The Tocriscreen 2.0 Compound Library contains bioactive compounds covering a diverse range of biomedical research areas; Neuroscience (41%), Cancer (32%), Endocrinology (10%), Cardiovascular (6%), Immunology (6%), Stem Cells (4%), other research areas (2%).
The Tocriscreen 2.0 Compound Library contains bioactive compounds covering a diverse range of molecular targets; 7-TM receptors (GPCRs; 27%), non-kinase enzymes (21%), kinases including enzyme-linked receptors (20%), ion channels (13%), cell biology targets (9%), nuclear receptors (6%), and transporters and other pharmacological targets (5%).
Danish et al (2021) A cellular assay for the identification and characterization of connexin gap junction modulators. Int.J.Mol.Sci. 22 1417 PMID: 33572565
Wazir et al (2021) Activity-based screening assay for mono-ADP-ribosylhydrolases. SLAS Discov. 26 67 PMID: 32527186
Yoon et al (2020) Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. BMB Rep. 53 166 PMID: 31964466
Duvall et al (2019) Small-molecule agonists of Ae. aegypti neuropeptide Y receptor block mosquito biting. Cell. 176 687 PMID: 30735632
Fiedler et al (2019) MAP4K4 inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo. Cell Stem Cell. 24 579 PMID: 30853557
Takeuchi et al (2019) Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor. PLoS One. 14 e0212233 PMID: 30779774
Mishra et al (2022) Improved loss-of-function CRISPR/Cas9 genome editing in human cells concomitant with inhibition of TGFβ signaling. Molecular Therapy: Nucleic Acid.